gal1

M617 acetate is a selective agonist of galanin receptor 1 (GAL1). M617 acetate acts through central GAL1, promotes GLUT4 expression, and enhances GLUT4 content in the cardiac muscle of type 2 diabetic rats. The Ki values are 0.23 and 5.71 nM for GAL1 and GAL2, respectively.

Galnon is a galanin receptor agonist, improves intrinsic cortical bone tissue properties

Gal1-β-3GlcNAc-β-PNP (Galactosyl-N-acetylglucosaminyl-β-p-nitrophenyl) is a biochemical reagent used in glycobiology studies. Research in glycobiology focuses on the structure, synthesis, biology, and evolution of sugars, encompassing carbohydrate chemistry, glycan formation and degradation enzymology, protein-glycan recognition, and the role of glycans in biological systems. This field is closely linked to fundamental research, biomedicine, and biotechnology.

Gal1-β-3GlcNAc1-β-Ome is a type of biochemical reagent used in glycobiology research. Glycobiology explores the structure, synthesis, biology, and evolution of sugars. This field encompasses carbohydrate chemistry, glycan formation and degradation enzymology, protein-glycan recognition, and the role of glycans in biological systems. It closely relates to fundamental research, biomedicine, and biotechnology.

Gal1-b-4GlcNAc-α-PNP is a reagent used in biochemical reactions.

Gal1-β-4GlcNAc-β-Bn (Benzyl β-D-galactopyranosyl-(1→4)-β-D-N-acetylglucosamine) is a biochemical reagent employed in glycobiology research. Glycobiology focuses on exploring the structure, synthesis, biology, and evolution of sugars, encompassing areas such as carbohydrate chemistry, glycan formation and degradation enzymology, protein-glycan recognition, and the roles of glycans within biological systems. This field is closely linked to fundamental research, biomedicine, and biotechnology.

Gal1-β-4GlcNAc1-β-6Gal is a biochemical reagent used in glycoscience research. Glycoscience examines the structure, synthesis, biology, and evolution of sugars. It encompasses carbohydrate chemistry, glycoconjugate formation and degradation enzymology, protein-glycan recognition, and the roles of glycans in biological systems. This field is closely linked to fundamental research, biomedicine, and biotechnology.

ST6GAL1-IN-1 (compound 4e) is a potent selective inhibitor of ST6GAL1, with an IC50 value of 20.0 μM. It demonstrates anti-metastatic activity by effectively inhibiting the migration of MDA-MB-231 cells. Furthermore, ST6GAL1-IN-1 is capable of suppressing tumor growth and metastasis in vivo.

Fuc1-α-2Gal1-β-3GlcNAc-β-PNP is a biochemical reagent utilized in glycoscience research. This field examines the structure, synthesis, biology, and evolution of sugars, encompassing studies in carbohydrate chemistry, glycans formation and degradation, protein-glycan interactions, as well as the role of glycans in biological systems. It closely relates to fundamental research, biomedicine, and biotechnology.

iKIX1 is an Pdr1-dependent gene activation. It re-sensitizes drug-resistant C. glabrata to azole antifungals in vitro and in animal models for disseminated and urinary tract C. glabrata infection.

Gal-1-IN-1 is a potent and selective inhibitor of human galectin-1 (hGal-1), with a Ki of 0.022 μM. It effectively blocks the binding of hGal-1 to tumor cells and inhibits the pro-apoptotic state induced by hGal-1. Additionally, Gal-1-IN-1 reduces the viability of cancer cells expressing hGal-1 and can be utilized in breast cancer research.

Thiodigalactoside (TDG), a non-metabolizable disaccharide, serves as an orally active, potent galectin (GAL) inhibitor, exhibiting Kd values of 24 μM and 49 μM for GAL1 and GAL3, respectively. Demonstrating anti-inflammatory and anti-cancer properties, it significantly diminishes body weight gain in diet-induced obese rats.

Galectin-3-IN-3 (Compound 4) serves as a selective and orally active inhibitor targeting Gal-3. It exhibits IC50 values of 11 nM for mGal-3 and 84 nM for hGal-3 [1].

Galectin-3-IN-5 (Compound 20) is an orally active inhibitor of galectin-3 (Gal-3), exhibiting an IC50 value of 9.2 nM against hGal-3.

ST3 β-Gal α-2,3-Sialyltransferase 1 (ST3GAL1) is a sialyltransferase enzyme that, when overexpressed in ovarian cancer cell lines, enhances cell growth, migration, and invasion, while also increasing tumorigenicity and resistance to paclitaxel in vivo. ST3GAL1 catalyzes the transfer of sialic acid from CMP-sialic acid to galactose-containing substrates and is useful in studies of cancer progression and chemotherapy resistance.

ST6 GalSialyltransferase1 (EC:2.4.3.1, ST6GAL1) catalyzes the transfer of sialic acid from CMP-sialic acid to substrates containing galactose.

M1145 acetate, a chimeric peptide, is a selective galanin receptor type 2 (GAL2) agonist, with a Ki of 6.55 nM. M1145 acetate shows more than 90-fold higher affinity for GAL2 over GAL1 (Ki=587 nM) and a 76-fold higher affinity over GalR3 (Ki=497 nM). M1145 acetate has an additive effect on the signal transduction of galanin[1].

M40 acetate is a potent, non-selective galanin receptor antagonist (Ki values are 1.82 and 5.1 nM at GAL1 and GAL2 respectively) that inhibits galanin (1-29) binding in rat brain in vitro (IC50 = 3 - 15 nM). Attenuates the antidepressant effects of fluoxetine and blocks galanin-induced food intake in vivo. Also exhibits weak partial agonist activity at peripheral GAL2 receptors at doses > 100 nM.

M871 acetate is a selective galanin GAL2 receptor antagonist (Ki values are 13.1 and 420 nM at GAL2 and GAL1 receptors, respectively).It blocks pronociceptive effects of GAL2 agonists including AR-M1896.

Galanin is a neuropeptide with diverse biological activities. [1][2][3][4][5] It binds to rat galanin (GAL) receptor subtypes GAL1-3 (IC50s = 0.339, 1.35, and 3.31 nM, respectively) and human GAL1-3 (IC50s = 0.288, 1.62, and 12.3 nM, respectively). [1] Galanin binds to and inhibits contraction of guinea pig gastric smooth muscle cells induced by carbachol . [2] In vivo, Galanin (6 nmol, i.c.v.) increases feeding behavior in rats and increases latency to hindpaw withdrawal in response to heat and mechanical stimulation in a rat model of carrageenin-induced inflammation when administered at a dose of 2 nmol injected into the nucleus accumbens.[3][4] Galanin (5 μg, i.c.v.) also inhibits acetylcholine release induced by scopolamine in the ventral hippocampus of freely moving rats. [5]

Galanin (Human) (Acetate) is a 30-amino acid neuropeptide and galanin (GAL) receptor agonist.It inhibits forskolin-induced cAMP production in HEK293E cells expressing recombinant human GAL1 receptors (EC50= 0.031 nM) and stimulates inositol phosphate accumulation in CHO cells expressing recombinant human GAL2receptors (EC50= 12.3 nM).Human galanin induces contractions in isolated rat longitudinal fundus strips with an EC50value of 13.8 nM.Intrathecal administration of human galanin (3, 10, and 30 nmol/animal) reduces paw licking and flinching in the second, but not first, phase of the formalin test in rats.

M617 TFA, a selective galanin receptor 1 (GAL1) agonist, exhibits dissociation constants (Kis) of 0.23 nM for GAL1 and 5.71 nM for GAL2. Through activation of GAL1, M617 TFA enhances GLUT4 expression and content in the cardiac muscle of type 2 diabetic rats [1] [2].

Galanin (1-29)(rat, mouse) TFA acts as a non-selective agonist for galanin receptors, exhibiting affinities (Kis) of 0.98 nM for GAL1, 1.48 nM for GAL2, and 1.47 nM for GAL3, respectively, and possesses an anticonvulsant effect [1] [2].

M1145 TFA, a chimeric peptide, acts as a selective agonist for the galanin receptor type 2 (GAL2), demonstrating a binding affinity (K i) of 6.55 nM. It exhibits significantly greater selectivity for GAL2, with over 90-fold and 76-fold higher affinity compared to GAL1 (K i = 587 nM) and GalR3 (K i = 497 nM), respectively. Additionally, M1145 TFA enhances galanin signal transduction mechanisms [1].